| The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody DM Benson Jr, CE Bakan, A Mishra, CC Hofmeister, Y Efebera, ... Blood, The Journal of the American Society of Hematology 116 (13), 2286-2294, 2010 | 940 | 2010 |
| MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly … R Garzon, S Liu, M Fabbri, Z Liu, CEA Heaphy, E Callegari, S Schwind, ... Blood, The Journal of the American Society of Hematology 113 (25), 6411-6418, 2009 | 916 | 2009 |
| Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver S Hsu, B Wang, J Kota, J Yu, S Costinean, H Kutay, L Yu, S Bai, ... The Journal of clinical investigation 122 (8), 2871-2883, 2012 | 828 | 2012 |
| The Broad Spectrum of Human Natural Killer Cell Diversity AG Freud, BL Mundy-Bosse, J Yu, MA Caligiuri Immunity 47 (5), 820-833, 2017 | 581 | 2017 |
| The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation T Liu, Q Wei, J Jin, Q Luo, Y Liu, Y Yang, C Cheng, L Li, J Pi, Y Si, H Xiao, ... Nucleic acids research 48 (7), 3816-3831, 2020 | 484 | 2020 |
| CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma J Chu, Y Deng, DM Benson, S He, T Hughes, J Zhang, Y Peng, H Mao, ... Leukemia 28 (4), 917-927, 2014 | 465 | 2014 |
| Location and cellular stages of natural killer cell development J Yu, AG Freud, MA Caligiuri Trends in immunology 34 (12), 573-582, 2013 | 431 | 2013 |
| Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses G Fulci, L Breymann, D Gianni, K Kurozomi, SS Rhee, J Yu, B Kaur, ... Proceedings of the National Academy of Sciences 103 (34), 12873-12878, 2006 | 398 | 2006 |
| Curcumin is a potent DNA hypomethylation agent Z Liu, Z Xie, W Jones, RE Pavlovicz, S Liu, J Yu, P Li, J Lin, JR Fuchs, ... Bioorganic & medicinal chemistry letters 19 (3), 706-709, 2009 | 385 | 2009 |
| First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia X Tang, L Yang, Z Li, AP Nalin, H Dai, T Xu, J Yin, F You, M Zhu, W Shen, ... American Journal of Cancer Research 8 (6), 1083, 2018 | 376 | 2018 |
| CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells J Han, J Chu, W Keung Chan, J Zhang, Y Wang, JB Cohen, A Victor, ... Scientific reports 5 (1), 11483, 2015 | 345 | 2015 |
| Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC SM Collins, CE Bakan, GD Swartzel, CC Hofmeister, YA Efebera, H Kwon, ... Cancer Immunology, Immunotherapy 62, 1841-1849, 2013 | 341 | 2013 |
| Pro-and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells J Yu, M Wei, B Becknell, R Trotta, S Liu, Z Boyd, MS Jaung, BW Blaser, ... Immunity 24 (5), 575-590, 2006 | 300 | 2006 |
| CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets J Yu, HC Mao, M Wei, T Hughes, J Zhang, I Park, S Liu, S McClory, ... Blood, The Journal of the American Society of Hematology 115 (2), 274-281, 2010 | 295 | 2010 |
| Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia S Liu, LC Wu, J Pang, R Santhanam, S Schwind, YZ Wu, CJ Hickey, J Yu, ... Cancer cell 17 (4), 333-347, 2010 | 289 | 2010 |
| TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells R Trotta, JD Col, J Yu, D Ciarlariello, B Thomas, X Zhang, J Allard, M Wei, ... The Journal of Immunology 181 (6), 3784-3792, 2008 | 276 | 2008 |
| Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells W Rao, H Wang, J Han, S Zhao, J Dumbleton, P Agarwal, W Zhang, ... ACS nano 9 (6), 5725-5740, 2015 | 271 | 2015 |
| Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance H Wang, Z Gao, X Liu, P Agarwal, S Zhao, DW Conroy, G Ji, J Yu, ... Nature communications 9 (1), 562, 2018 | 270 | 2018 |
| Interleukin-1β selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue T Hughes, B Becknell, AG Freud, S McClory, E Briercheck, J Yu, C Mao, ... Immunity 32 (6), 803-814, 2010 | 246 | 2010 |
| The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector W Dong, X Wu, S Ma, Y Wang, AP Nalin, Z Zhu, J Zhang, DM Benson, ... Cancer discovery 9 (10), 1422-1437, 2019 | 239 | 2019 |
Guido MarcucciCity of HopeVerified email at coh.org
